Treatment with the SGLT2 inhibitor luseogliflozin improves nonalcoholic steatohepatitis in a rodent model with diabetes mellitus

Shirong Qiang,Yusuke Nakatsu,Yasuyuki Seno,Midori Fujishiro,Hideyuki Sakoda,Akifumi Kushiyama,Keiichi Mori,Yasuka Matsunaga,Takeshi Yamamotoya,Hideaki Kamata,Tomoichiro Asano

Treatment with the SGLT2 inhibitor luseogliflozin improves nonalcoholic steatohepatitis in a rodent model with diabetes mellitus

2015

Shirong Qiang
Yusuke Nakatsu
Yasuyuki Seno
Midori Fujishiro
Hideyuki Sakoda
Akifumi Kushiyama
Keiichi Mori
Yasuka Matsunaga
Takeshi Yamamotoya
Hideaki Kamata
Tomoichiro Asano

Background Insulin resistance with elevated glucose is a risk factor for non-alcoholic steatohepatitis (NASH). We investigated the effects of the sodium glucose cotransporter 2 (SGLT2) inhibitor luseogliflozin on NASH development using a rodent model.

Keywords:

SGLT2 Inhibitor
Luseogliflozin
Steatohepatitis
Insulin resistance
Risk factor
Endocrinology
Internal medicine
Sodium/Glucose Cotransporter 2
Diabetes mellitus
Medicine
rodent model

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations